Caroline Seymour

Managing Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com

Articles

Expert Highlights Precision Medicine Advances in GI Cancers

March 21st 2018

Eric A. Collisson, MD, discusses ongoing efforts to advance precision medicine in GI malignancies to improve the standard of care.

Expert Makes Case for Hypofractionation in Prostate Cancer

March 19th 2018

Howard M. Sandler, MD, discusses the emergence of hypofractionation as a viable treatment approach for patients with prostate cancer.

Chemotherapy May Be Vital to Long-Term Immunotherapy Efficacy in Bladder Cancer

March 14th 2018

Parminder Singh, MD, discusses the potential of immunotherapy, the importance of sequencing to avoid disease progression, and the use of chemotherapy and radiation therapy to reach an unmet need in muscle-invasive bladder cancer.

Expert Discusses Optimizing HIFU and Other Strategies in Prostate Cancer

March 14th 2018

Timothy J. Daskivich, MD, discusses the use of High-intensity focused ultrasound and other treatment strategies in the prostate cancer armamentarium.

Expert Discusses Developments, Challenges With Radiation in NSCLC

March 13th 2018

Holger L. Gieschen, MD, discusses the latest developments with radiation therapy in non-small cell lung cancer.

Cytoreductive Nephrectomy Retains Role in Modern RCC Era

March 10th 2018

James Wysock, MD, discusses the evolution of cytoreductive nephrectomy in renal cell carcinoma.

2018 Ushers in New Era of Prostate Cancer Treatment

March 9th 2018

Edwin M. Posadas, MD, discusses the evolution of prostate cancer therapy, including the earlier use of advanced-stage agents and the potential for immunotherapy in the field.

Expert Sheds Light on Future of Targeted Treatment in NSCLC

March 9th 2018

David C. Portnoy, MD, discusses emerging developments with targeted agents in lung cancer.

Figlin Discusses Optimizing Expanding Treatment Options in RCC

March 8th 2018

Robert A. Figlin, MD, discusses the expanding RCC armamentarium and balancing the benefits and risks of standard and emerging treatments to achieve optimal outcomes.

Hematopathologist Highlights Latest Developments in the Field

March 8th 2018

Nichon L. Grupka, MD, discusses advances in hematopathology, specifically mutations as prognostic indicators, disease-associated versus disease-causing mutations, and advice for physicians who are working to navigate the field.

Apalutamide Approval Paves Way for Further Advances in Nonmetastatic CRPC

March 7th 2018

Alan H. Bryce, MD, discusses emerging agents and next steps in the treatment of patients with in nonmetastatic prostate cancer.

Perl Highlights Latest CAR T-Cell Therapy Advances

March 5th 2018

Alexander Perl, MD, discusses the implementation of CAR T-cell therapy in ALL and other advances with this unique treatment across the spectrum of hematologic malignancies.

Expert Highlights Game-Changing Therapies for Acute Leukemia

March 5th 2018

William Donnellan, MD, discusses recent FDA approvals for the treatment of patients with AML and ALL, and highlighted emerging agents in the pipeline.

Levy Lends Insight on Pivotal NSCLC Trials

March 2nd 2018

Benjamin P. Levy, MD, highlights trials that continue to shape the treatment landscape for patients with lung cancer.

Expert Calls for Cross-Communication in NSCLC Treatment Decisions

March 1st 2018

Shirley Michelle Shiller, DO, discusses the application of biomarkers and the importance of educating practitioners on treatment advancements in NSCLC.

Strosberg Discusses Lutathera Approval, Remaining Challenges in NETs

March 1st 2018

Jonathan R. Strosberg, MD, discusses ongoing advances and challenges in the treatment of patients with NETs.

Optimizing Genetic Testing Remains Challenge in Hematologic Malignancies

March 1st 2018

Andrew Laramore, MD, discusses the evolution of genetic testing in hematologic cancers and optimal methods of detection.

Expert Highlights Progress With Molecular Biomarkers in GI Cancers

March 1st 2018

Michael J. Pishvaian, MD, discusses expanded testing for biomarkers, using liquid biopsies to predict response to treatment, and the importance of identifying increasingly specific subsets of GI cancers to make treatment decisions.

Potentially Transformative Treatments Emerge in Pancreatic Cancer

March 1st 2018

Allyson Ocean, MD, discusses the development of novel therapeutic regimens in pancreatic cancer.

Expert Highlights Immunotherapy Use in Stage III NSCLC

February 28th 2018

Gary Schwartz, MD, discusses the significance of the PACIFIC trial and applications of immunotherapy for patients with stage III locally advanced disease.